MELLARIL
LOE ApproachingNDAORALCONCENTRATEPriority Review
Approved
Mar 1962
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MELLARIL is an oral concentrate small-molecule antipsychotic approved in 1962 by Novartis. The specific mechanism of action and clinical indications are not documented in available data. This is a legacy product in the mature/declining phase of its commercial lifecycle.
LOE Approaching
This legacy product faces LOE pressure with moderate competitive intensity (30/100); expect smaller team sizes and focus on managed decline rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on MELLARIL offers limited growth trajectory and minimal linked job postings (0 open roles). This assignment is best suited for professionals managing mature portfolios, optimizing cost-effectiveness, or preparing for product lifecycle transitions. Career development will focus on operational excellence and managed decline rather than innovation or expansion.
Brand Manager
Worked on MELLARIL at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.